Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept Dosing Regimens in nAMD
NCT02540954Phase 3Completed
- Sponsor
- Bayer
- Start
- Sep 2015
- Primary completion
- Dec 2019
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 14
01
Overview
A Phase 3 trial of aflibercept in neovascular age-related macular degeneration (NVAMD), sponsored by Bayer. Started Sep 2015; status: completed.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02540954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02540954.